NT5E and neoplasm: Although no broad adverse safety effects have been reported in clinical studies targeting CD73 with systemically administered antibodies Harvey et al., 2020; Siu et al., 2018, a strategy to reduce the risk of targeting non-tumor tissue has been to engineer the antibodies without Fc receptor engagement.